- Trial phase
- Approved (China NMPA)
- Time to market
- Already approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). No US FDA filing has been announced; US approval is estimated in the 2027-2028 window if Eli Lilly initiates and completes global Phase 3 trials.
- Why 3/10
- No hard binary catalyst is scheduled for mazdutide in the next ~12 months. The drug is already approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). OPKO is a passive royalty holder, not the developer. A US FDA filing by Eli Lilly is not expected before 2027-2028. Without a dated PDUFA, pivotal readout or AdComm, the impactScore is capped at 3-5 per the rubric; the score of 3 reflects that mazdutide is an approved, commercial-stage asset with no pending regulatory decision and that OPKO's exposure is limited to a royalty stream that has already been partially monetized.
Watch OPKO's quarterly royalty revenue from mazdutide as a gauge of China commercial uptake. Innovent's product revenue grew over 40% YoY in Q3 2026, but OPKO's specific royalty share is not separately disclosed. No near-term binary catalyst exists for this asset; the next potential catalyst would be Eli Lilly announcing a US Phase 3 program or FDA filing, which is not expected before 2027-2028.
Price Chart
Executive Summary
Mazdutide (brand name Xinermei in China, development codes IBI362/LY3305677) is a once-weekly GLP-1/glucagon dual receptor agonist for weight management and type 2 diabetes. It was developed by Eli Lilly and licensed to Innovent Biologics for China, where it received NMPA approval in June 2025 (weight management) and September 2025 (type 2 diabetes). Phase 3 trials (GLORY-1, GLORY-2) showed 14-20% weight loss. The drug is not FDA-approved in the US. OPKO Health (NASDAQ: OPK) holds a royalty interest through a licensing agreement with Eli Lilly, recording its first mazdutide royalty revenue in 2025 ($4.3M in Q4 2025). In August 2026, OPKO raised $125M in senior secured notes backed by future mazdutide royalty payments, capping repayment at 1.5x funded while retaining long-term upside. OPKO is a passive royalty recipient, not the drug's developer or commercializer.
How It Works
Mazdutide is a once-weekly injectable drug that activates two natural hormone receptors at the same time: GLP-1 (which suppresses appetite and slows digestion) and glucagon (which increases energy expenditure and fat burning). This dual mechanism is designed to produce greater weight loss than drugs that only target GLP-1 alone.
Trial Status
Mazdutide is approved in China for both chronic weight management (June 2025) and type 2 diabetes (September 2025). Phase 3 trials GLORY-1 (NEJM 2025, 14% weight loss at 6mg) and GLORY-2 (JAMA 2026, 18.55% weight loss at 9mg) were completed in Chinese adults. The DREAMS-3 Phase 3 head-to-head trial versus semaglutide showed mazdutide superiority on glycemic control and weight loss (presented at ADA 2026). A US Phase 2 trial in obesity/overweight completed and was published in The Lancet Diabetes & Endocrinology (2026). A Phase 2 trial in alcohol use disorder (NCT06817356) completed in May 2026. No US Phase 3 program has been announced by Eli Lilly.
The Two-Sided Case
Upcoming Catalysts
- Quarterly mazdutide royalty revenue disclosures in OPKO earnings reports (next: Q4 2026, expected early 2027)
- Potential Eli Lilly announcement of US Phase 3 program or FDA filing timeline (no date confirmed; estimated 2027-2028)
- China commercial sales growth trajectory as Innovent continues mazdutide rollout
Source Filing
The SecBot filing or press-release report that triggered this drug report:
OPKO Health, Inc. PRESS-RELEASE OPK ·Originating report